【四环医药(00460.HK)：惠升生物研发的重磅产品德谷门冬双胰岛素注射液惠优加®获批上市】智通财经APP讯，四环医药(00460.

智通财经08-06

【四环医药(00460.HK)：惠升生物研发的重磅产品德谷门冬双胰岛素注射液惠优加®获批上市】智通财经APP讯，四环医药(00460.HK)公布，该集团旗下非全资附属公司惠升生物制药股份有限公司研发的德谷门冬双胰岛素注射液(商品名：惠优加®)已获中华人民共和国国家药品监督管理局批准上市，用于治疗成人2型糖尿病。是继塬研诺和诺德后国产首个获批上市的德谷门冬双胰岛素注射液生物类似药。

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2457405769?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-08-06 12:04","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2457405769","market":"us","top_or_hot":-1,"title":"【四环医药(00460.HK)：惠升生物研发的重磅产品德谷门冬双胰岛素注射液惠优加®获批上市】智通财经APP讯，四环医药(00460.","media":"智通财经","content":"<div>\n<p>【四环医药(00460.HK)：惠升生物研发的重磅产品德谷门冬双胰岛素注射液惠优加®获批上市】智通财经APP讯，四环医药(00460.HK)公布，该集团旗下非全资附属公司惠升生物制药股份有限公司研发的德谷门冬双胰岛素注射液(商品名：惠优加®)已获中华人民共和国国家药品监督管理局批准上市，用于治疗成人2型糖尿病。是继塬研诺和诺德后国产首个获批上市的德谷门冬双胰岛素注射液生物类似药。</p>\n\n<a href=\"https://www.zhitongcaijing.com/immediately.html?type=ganggu\">网页链接</a>\n\n</div>\n","source":"live_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>7x24快讯</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n7x24快讯\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-06 12:04 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.zhitongcaijing.com/immediately.html?type=ganggu><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>【四环医药(00460.HK)：惠升生物研发的重磅产品德谷门冬双胰岛素注射液惠优加®获批上市】智通财经APP讯，四环医药(00460.HK)公布，该集团旗下非全资附属公司惠升生物制药股份有限公司研发的德谷门冬双胰岛素注射液(商品名：惠优加®)已获中华人民共和国国家药品监督管理局批准上市，用于治疗成人2型糖尿病。是继塬研诺和诺德后国产首个获批上市的德谷门冬双胰岛素注射液生物类似药。</p>\n\n<a href=\"https://www.zhitongcaijing.com/immediately.html?type=ganggu\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BZ1G4Q59.USD","symbol_name":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","start_time":0,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","article_id":"2457405769","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2457405769","pubTimestamp":1722917096,"sourceInfo":{"source_id":"live_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"【四环医药(00460.HK)：惠升生物研发的重磅产品德谷门冬双胰岛素注射液惠优加®获批上市】智通财经APP讯，四环医药(00460.HK)公布，该集团旗下非全资附属公司惠升生物制药股份有限公司研发的","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK1515":"抗疫概念","BK1191":"制药","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK1593":"医美概念股","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","00460":"四环医药","BK4007":"制药","NVO":"诺和诺德","BK4532":"文艺复兴科技持仓","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK1600":"工业大麻"},"translate_title":"[Sihuan Pharmaceutical (00460. HK): The blockbuster product Degu Aspart Double Insulin Injection developed by Huisheng Biotech Huiyoujia ® was approved for marketing] Zhitong Finance APP News, Sihuan Pharmaceutical","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00460":1,"NVO":1},"content_text":"【四环医药(00460.HK)：惠升生物研发的重磅产品德谷门冬双胰岛素注射液惠优加®获批上市】智通财经APP讯，四环医药(00460.HK)公布，该集团旗下非全资附属公司惠升生物制药股份有限公司研发的德谷门冬双胰岛素注射液(商品名：惠优加®)已获中华人民共和国国家药品监督管理局批准上市，用于治疗成人2型糖尿病。是继塬研诺和诺德后国产首个获批上市的德谷门冬双胰岛素注射液生物类似药。","kind":null,"is_publish_news":false,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2457405769"}